MVD and neoplasm: Relative to A-I KO, day 7 B16F10L melanoma tumor homografts from A-I Tg+/– exhibited reduced expression of mevalonate-5-pyrophosphate decarboxylase (Mvd), a key enzyme targeted in cancer therapy, along with a number of key genes in the sterol synthesis arm of the mevalonate pathway.